Erasca stock sinks almost 50% after patient death in cancer drug trial

A 66-year-old man developed severe lung inflammation about a month after starting ERAS-0015 and later died after withdrawing supportive care

Credit: Yahoo Finance

Erasca stock fell about 46% Tuesday after the San Diego-based cancer drug developer disclosed that a patient died following severe side effects in an early-stage clinical trial.

About a month into treatment with ERAS-0015, Erasca's experimental pan-RAS molecular glue, the 66-year-old man — who had metastatic pancreatic cancer — was hospitalized with grade 3 pneumonitis, a serious form of lung inflammation. Doctors halted the drug and initiated aggressive treatment including high-dose steroids, but the patient ultimately decided to discontinue supportive care, and he........

© Quartz